Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit the Swiss pharma bought for $4.3 billion in 2019. Roche described the restructuring in its ...

BGI Genomics and Roche Diagnostics have rolled out tests for Alzheimer's disease in China, the companies said, in an effort ...

Roche has logged a few clinical successes lately, but hasn't scored the sort of big wins that change investment theses or drive lasting changes in sentiment. Fourth quarter pharmaceutical sales were ...

Biologic medicines are making inroads into chronic obstructive pulmonary disease (COPD), with two blockbuster antibodies expanding their FDA-approved uses to this lung disorder in the past year. A ...

Roche said Monday it plans to invest up to $550 million and add hundreds of jobs over the next five years at its Indianapolis-based diagnostics unit. The Swiss pharmaceutical and diagnostics giant ...

Roche is a relative latecomer to GLP-1 metabolic disorder drugs, but an oral drug candidate that came as part of a $2.7 billion acquisition last year now has preliminary early-stage clinical data that ...

Roche has removed eight phase 1 and 2 oncology and neurology candidates from its pipeline as part of a set of “trade-offs” intended to “increase the overall portfolio value and speed up development.” ...

If you are wondering whether Roche Holding is still an attractive opportunity after its recent run, or whether that value is already reflected in the price, this article will walk through what the ...